<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_sjph-2021-0005_s_006">
<h3>Introduction</h3>
<p>Introduction: To estimate the procedure-related risks of pregnancy loss following chorionic villus sampling (CVS) and amniocentesis (AC) compared to pregnancies without procedure.</p>
</sec>
<sec id="j_sjph-2021-0005_s_007">
<h3>Methods</h3>
<p>This cohort study enrolled all women who underwent CVS or AC at the Department of Perinatology, University Medical Centre, Ljubljana, Slovenia (from January 2013 to June 2015). For each group we obtained a maternal age and gestational age (11–14 weeks for CVS and >15 weeks for AC) for a matched control group without invasive procedures from the national database. The data was obtained from hospital records and telephone surveys concerning pregnancy outcomes. Pregnancy loss rates in intervention vs. control groups were compared by generating relative risk (RR) with a 95% confidence interval.</p>
</sec>
<sec id="j_sjph-2021-0005_s_008">
<h3>Results</h3>
<p>During the study period, 828 women underwent CVS and 2,164 women underwent AC. Complete outcome data was available in 2,798 cases (93.5%, 770 CVS, 2,028 AC). Pregnancy loss occurred in 8/770 (1.04%, 95% CI 0.4–2.0%) after CVS vs. 15/1130 (1.33%, 95% CI 0.8–2.2%) in matched control (RR 0.8, 95% CI 0.33–1.8, p=0.6). It occurred in 16/2028 (0.79%, 95% CI 0.5–1.3%) after AC vs. 14/395 (3.29%, 95% CI 2.1–5.8%) in matched control (RR 0.2, 95% CI 0.11–0.45, p&lt;0.0001).</p>
</sec>
<sec id="j_sjph-2021-0005_s_009">
<h3>Conclusion</h3>
<p>The pregnancy loss rates after CVS and AC were comparable to losses in pregnancies without these procedures. With the increasing use of non-invasive prenatal testing, information that the invasive procedures are safe when indicated is essential.</p>
</sec>
</abstract>

Introduction
Introduction: To estimate the procedure-related risks of pregnancy loss following chorionic villus sampling (CVS) and amniocentesis (AC) compared to pregnancies without procedure.


Methods
This cohort study enrolled all women who underwent CVS or AC at the Department of Perinatology, University Medical Centre, Ljubljana, Slovenia (from January 2013 to June 2015). For each group we obtained a maternal age and gestational age (11–14 weeks for CVS and >15 weeks for AC) for a matched control group without invasive procedures from the national database. The data was obtained from hospital records and telephone surveys concerning pregnancy outcomes. Pregnancy loss rates in intervention vs. control groups were compared by generating relative risk (RR) with a 95% confidence interval.


Results
During the study period, 828 women underwent CVS and 2,164 women underwent AC. Complete outcome data was available in 2,798 cases (93.5%, 770 CVS, 2,028 AC). Pregnancy loss occurred in 8/770 (1.04%, 95% CI 0.4–2.0%) after CVS vs. 15/1130 (1.33%, 95% CI 0.8–2.2%) in matched control (RR 0.8, 95% CI 0.33–1.8, p=0.6). It occurred in 16/2028 (0.79%, 95% CI 0.5–1.3%) after AC vs. 14/395 (3.29%, 95% CI 2.1–5.8%) in matched control (RR 0.2, 95% CI 0.11–0.45, p<0.0001).


Conclusion
The pregnancy loss rates after CVS and AC were comparable to losses in pregnancies without these procedures. With the increasing use of non-invasive prenatal testing, information that the invasive procedures are safe when indicated is essential.

Pregnancy loss after amniocentesis and chorionic villus sampling: Cohort study

Slovenian Journal of Public Health

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Neuspela nosečnost po amniocentezi in biopsiji horionskih resic: Kohortna študija

Introduction
Introduction: To estimate the procedure-related risks of pregnancy loss following chorionic villus sampling (CVS) and amniocentesis (AC) compared...

Variables		CVS	AC
Baseline characteristics	Gravida
	Primipara	207 (25.0%)	536 (24.8%)
	Multipara	621 (75.0%)	1,628 (75.2%)
	Previous miscarriage
	None	468 (56.5%)	1,214 (56.1%)
	≤2	327 (39.5%)	841 (38.9%)
	>2	33 (4.0%)	109 (5.0%)
	Indications
	Advanced maternal age	290 (35.0%)	1,308 (60.4%)
	Positive result at screening test	363 (43.8%)	367 (17.0%)
	Ultrasound abnormality	12 (1.4%)	163 (7.5%)
	Genetic syndrome in family	84 (10.1%)	78 (3.6%)
	More than one indication	76 (9.2%)	164 (7.6%)
	Toxoplasma gondii seroconversion	0 (0.0%)	56 (2.6%)
	On demand	2 (0.2%)	19 (0.9%)
	Other	1 (0.1%)	9 (0.4%)
Complications	No complications	732 (95.1%)	1,924 (94.9%)
	Minor complications	29 (3.8%)	75 (3.7%)
	Chorioamnionitis with delivery at term	1 (0.1%)	1 (0.0%)
	PPROM	0 (0.0%)	12 (0.6%)
	Miscarriage after procedure	8 (1.04%)	16 (0.8%)

Pregnancy loss after amniocentesis and chorionic villus sampling: Cohort study

Article Category: Research Article

Pubblicato online: 31 dic 2020

Pagine: 25 - 29

Ricevuto: 22 mag 2020

Accettato: 19 nov 2020

DOI: https://doi.org/10.2478/sjph-2021-0005

Parole chiave
pregnancy loss, amniocentesis, chorionic villus sampling, prenatal diagnosis

© 2021 National Institute of Public Health, Slovenia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Characteristics and subsequent complications in the CVS and AC group given as a number and percentage.

Pregnancy loss after amniocentesis and chorionic villus sampling: Cohort study

Article Category: Research Article

Pubblicato online: 31 dic 2020

Pagine: 25 - 29

Ricevuto: 22 mag 2020

Accettato: 19 nov 2020

DOI: https://doi.org/10.2478/sjph-2021-0005

Parole chiavepregnancy loss, amniocentesis, chorionic villus sampling, prenatal diagnosis

© 2021 National Institute of Public Health, Slovenia

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Characteristics and subsequent complications in the CVS and AC group given as a number and percentage.

Parole chiave
pregnancy loss, amniocentesis, chorionic villus sampling, prenatal diagnosis